Sep 2026· Protein Science· Vol 35· 0 citations· 19 references
Medicine
TL;DR
It is demonstrated that KLHDC2 can accommodate non-carboxylate scaffolds and expands the chemical space for developing KLHDC2-based targeted protein degradation strategies and expands the chemical space for developing KLHDC2-based targeted protein degradation strategies.
Abstract
Expanding the repertoire of usable E3 ubiquitin ligases remains a critical challenge in the field of targeted protein degradation. For the emerging E3 ligase Kelch domain‐containing protein 2 (KLHDC2), currently reported ligands have a carboxylate moiety in common that mimics the natural degron but compromises cellular permeability. Here we report the discovery of carboxylate‐free ligands for KLHDC2 through high‐throughput screening and cellular functional evaluation. A fluorescence polarization‐based screening assay identified NL1 as a micromolar KLHDC2 binder, which was confirmed by orthogonal biophysical methods. Although the structure–activity study did not improve affinity, a degron reporter assay demonstrated measurable cellular target engagement. Encouraged by these results, an expanded screen further identified NL2 as a neutral ligand with improved cellular activity. Computational analysis suggests that NL2 adopts a distinct binding mode, in which the conformational flexibility of two loops of KLHDC2 enables accommodation of its aromatic scaffold, while hydrophobic and π‐driven interactions compensate for the canonical ionic contacts of other carboxylate‐containing ligands. This work demonstrates that KLHDC2 can accommodate non‐carboxylate scaffolds and expands the chemical space for developing KLHDC2‐based targeted protein degradation strategies.
The first small-molecule GPX4 degraders that incorporate either electrophilic warheads or a minimal azide group as an E3 recruitment ligand are reported, thereby expanding the E3 ligase toolbox and offering a promising strategy for targeted cancer therapy.
Ze-Hong Lin, Kang Duan, Rui Wan et al.· Advancement of science· 0 citations
KLHL12 is identified as a potentially tumor-selective E3 ligase and the development of the first-in-class KLHL12-recruiting PROTACs are reported, which established KLHL12 as a promising tumor‑selective E3 ligase and provided a KLHL12-recruiting PROTAC platform for cancer therapy.
Shicheng Xu, Xian Zhang, Shun-Bo Hu et al.· Angewandte Chemie· 0 citations
This study establishes C367 as a druggable covalent site in the historically challenging STAT3 DBD, validates FEP-guided optimization of covalent inhibitors, and identifies compound 16 as a promising next-generation lead with a superior drug-like profile for targeting STAT3-dependent cancers.
Yang-Ping Deng, H. Bian, Feng-Yuan Zhang et al.· Journal of Chemical Informat...· 0 citations
Experimental strategies to identify UID degrons that mediate degradation by the catalytic 20S proteasome particle are described and an integrated workflow-spanning degron mapping to functional validation-provides a generalizable framework for uncovering ubiquitin-independent degrons.
Y. Shaul· Methods in molecular biology· 0 citations
A novel proximity-driven on-bead functional screening platform for the discovery of noninhibitory DUB ligands and generated DUBTACs, effectively stabilized CFTR protein levels in cells, demonstrating the potential of this platform for discovering DUB recruiters and facilitating the development of targeted protein stabi...
Kate E. Young, Janitha Kumarathunga, H. Kandambi et al.· bioRxiv· 0 citations
This review summarizes the development of classical small-molecule E3 ligase ligands and highlights emerging biological recruitment strategies involving antibodies, nanobodies, aptamers, peptides, and engineered proteins that provide greater programmability and selectivity.
Xuan Zhao, Yu-Han Liu, Xu-Cong Teng· Handbook of Experimental Pha...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.